Trials / Unknown
UnknownNCT05349409
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
A Phase Ⅰb/Ⅱ Clinical Study on the Dosage Exploration and Efficiency Expansion of SHR-A1811 for Injection in Combination With Fluzoparib Capsule in HER2-Expressing Advanced Solid Tumors of Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 212 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate safety, tolerability and preliminary efficacy of SHR-A1811 for Injection in combination with Fluzoparib Capsule for HER2-expressing advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for HER2-expressing advanced malignant tumors of patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 | SHR-A1811 for Injection: Given IV. |
| DRUG | Fluzoparib Capsule | Fluzoparib Capsule: Given PO. |
Timeline
- Start date
- 2022-06-09
- Primary completion
- 2024-11-30
- Completion
- 2025-05-31
- First posted
- 2022-04-27
- Last updated
- 2022-06-30
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05349409. Inclusion in this directory is not an endorsement.